Trident Texofab (540726)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Trident Texofab is exactly the kind of small-cap that demands caution. At ₹41.02, the market cap is only ₹42 crore, and the stock trades at 33.7 times trailing earnings and 2.8 times book value. Book value is ₹14.69, so I am paying nearly three rupees for every rupee of net assets. That is not a Graham-style margin of safety. Return on equity of 17.96% looks good on the surface, but return on capital employed is just 10.06%, so the efficiency picture is only moderate; debt/equity is not given. The top line is shrinking: sales growth is -18.78%. Yet reported profit growth jumped 150%—when revenue falls and profit jumps, I ask whether this is sustainable operating leverage, cost cutting, or a low-base illusion. The latest quarter shows sales of ₹26 crore and net profit of ₹1 crore; that is a thin margin, and annualising the profit would make the stock look cheaper, but one quarter is not a trend. The 52-week range is alarming: from ₹379 down to ₹38.57, now ₹41.02. Losing nearly 90% of value in a year is not the signature of a stable business. The Piotroski score of 6 out of 9 is middling, and there is no dividend. A PEG of 0.22 simply reflects the 150% profit growth; but PEG assumes growth will persist, and with sales falling that assumption is unsafe. I would need years of stable earnings, stronger margins, lower debt, and clear promoter holding before I could call this a wonderful business at a fair price. Right now it looks more like a turnaround speculation than a value investment. I will watch from the sidelines.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer